SCHEMBL3373201

SCHEMBL3373201

COC(=O)c1cc(-c2cnc(Nc3cc(C#N)cc(OC)c3)nc2-n2nc(C(F)(F)F)cc2C)cnc1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAPK1 P53355 3/20 0.36
SYK P43405 2/20 0.36
TYRO3 Q06418 1/20 0.36
MERTK Q12866 1/20 0.36
MAPT P10636 2/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
STIM1 Q13586 1/20 0.34
ORAI1 Q96D31 1/20 0.34
MAPK3 P27361 1/20 0.34
KDM4E B2RXH2 1/20 0.34
SAE1 Q9UBE0 1/20 0.34
UBA2 Q9UBT2 1/20 0.34
LCK P06239 2/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
CSF1R P07333 2/20 0.33
NUAK1 O60285 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3451441 0.94 SYK (0.39) DAPK1SYKTYRO3MERTKMAPT
SCHEMBL3373538 0.94 TYRO3 (0.39) DAPK1SYKTYRO3MERTKMAPT
SCHEMBL3448553 0.93 SYK (0.41) SYKCYP2C9CYP2C19
SCHEMBL3451517 0.92 SYK (0.35) SYKTYRO3MERTKCYP2C9CYP2C19
SCHEMBL3450410 0.90 SYK (0.40) DAPK1SYKTYRO3MERTKHDAC3
SCHEMBL3449355 0.90 CNR2 (0.41) SYKLCKBTKCNR2
SCHEMBL3448520 0.90 DAPK1 (0.38) DAPK1SYKTYRO3MERTKMAPT
SCHEMBL3449921 0.89 CNR2 (0.37) DAPK1SYKTYRO3MERTKMAPT
SCHEMBL3373077 0.88 SYK (0.41) DAPK1SYKTYRO3MERTKMAPT
SCHEMBL3448384 0.88 SYK (0.44) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD DAPK1 3761/4885SYK 804/4885TYRO3 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.